Kezar Life Sciences Inc Stock

$4.51

5.85% day before yesterday

Nasdaq, Jul 11, 10:00 pm CET

ISIN

US49372L1008

Symbol

KZR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Kezar Life Sciences Inc Stock price

$4.51

-43.49 90.60% 5Y

Nasdaq, Closing price Fri, Jul 11 2025

-0.28 5.85%

ISIN

US49372L1008

Symbol

KZR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$33.0m

Enterprise Value

$-72.3m

Net debt

positive

Cash

$114.4m

Shares outstanding

7.3m

Valuation (TTM | estimate)

P/E

- | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

1.1

P/B

0.3

Financial Health

Equity Ratio

80.8%

Return on Equity

-71.6%

ROCE

ROIC

Debt/Equity

0.1

Financials (TTM | estimate)

Revenue

- | $0.0

EBITDA

- | -

EBIT

- | $-77.1m

Net Income

- | $-61.0m

Free Cash Flow

$-68.6m

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Kezar Life Sciences Inc Stock Analysis

Unlock Scores for Free

??

10 Analysts have issued a Kezar Life Sciences Inc forecast:

6x Buy

60%

4x Hold

40%

More details on Analyst Estimates Including Price Targets

10 Analysts have issued a Kezar Life Sciences Inc forecast:

Buy

60%

Hold

40%

Analyst Estimates with Stock Price Targets

Financial data from Kezar Life Sciences Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	17 17	37% 37% -
- Research and Development Expense	49 49	43% 43% -
EBITDA	-64 -64	38% 38% -
- Depreciation and Amortization	1.04 1.04	3% 3% -
EBIT (Operating Income) EBIT	-65 -65	38% 38% -
Net Profit	-62 -62	39% 39% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Kezar Life Sciences Inc Stock News

Neutral

Business Wire

●

about 2 months ago

Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Chief Executive Officer and Co-founder, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4,...

Neutral

Business Wire

●

2 months ago

Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. “We shared exciting results this quarter from the PORTOLA trial, th...

Neutral

Seeking Alpha

●

4 months ago

Kezar Life Sciences, Inc. (KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call (Transcript)

Kezar Life Sciences, Inc. (NASDAQ:KZR ) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call March 25, 2025 8:00 AM ET Company Participants Chris Kirk - Chief Executive Officer & Co-Founder Dr. Craig Lammert - Principal Investigator of PORTOLA Study Gideon Hirschfield - Professor University of Toronto, Autoimmune Liver Disease Research Conference Call Participants Matt Phipp...

More Kezar Life Sciences Inc News

Company Profile

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco, California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Head office	United States
CEO	Christopher Kirk
Employees	55
Founded	2015
Website	kezarlifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now